



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2813-D

LYMAN, Stewart D. and
BECKMANN, M. Patricia

Serial No.: -- to be assigned --

Examiner: Unknown

Filing Date: March 7, 1994

Group Art Unit: Unknown

For: LIGANDS FOR FLT3 RECEPTORS

STATEMENT UNDER 37 CFR 1.821(e)

BOX SEQUENCE

The Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Applicants by their undersigned attorney hereby state that no computer readable form of the Sequence Listing is necessary for this application because the sequences provided in this application are identical to those in the computer readable form submitted for and with the following patent application:

Applicants: Stewart D. Lyman and M. Patricia Beckmann
Serial No.: 08/162,407
Filed: December 3, 1993
Title: LIGANDS FOR FLT3/FLK-2 RECEPTORS

Respectfully submitted,

Stephen L. Malaska
Attorney for Applicant
Registration No. 32,655

Date: 3/7/94


Immunex Corporation
Legal Affairs Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date listed below, and is addressed to the Commissioner of Patents and Trademarks, BOX SEQUENCE, Washington, D.C. 20231.

Date: 3/7/94

Signed: Kimberly B. Porter



not comply with 37 CFR 1.821-1.825, and detailed instructions as to the steps to be taken to gain compliance.

Respectfully submitted,

Stephen L. Malaska
Attorney for Applicant
Registration No. 32,655
Telephone (206) 587-0430

Legal Affairs Department
Immunex Corporation
51 University Street
Seattle, WA 98101

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Commissioner of Patent and Trademarks,
Washington, D.C. 20231, on May 16, 1994

Kimberly Porter
(Signature)

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7.

Other: _____

Applicant must provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.